Logo Image

Rahul Banerjee, MD, FACP

Articles by Rahul Banerjee, MD, FACP

9 Experts are featured in this series.

Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple Myeloma

ByEhsan Malek, MD ,Peter Leif Bergsagel, MD,Rahul Banerjee, MD, FACP,Krina Patel, MD, MSc ,Tiffany Richards, PhD, ANP-BC, AOCNP ,Rafael Fonseca, MD,Sridevi Rajeeve, MD ,C. Ola Landgren, MD, PhD

Panelists discuss how the use of CAR T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma could potentially improve long-term outcomes, considering factors such as patient selection, optimal timing, and the impact on subsequent treatment options.

9 Experts are featured in this series.

Bispecific Selection in BCMA-failed Therapy for Relapsed Refractory Multiple Myeloma

ByEhsan Malek, MD ,Peter Leif Bergsagel, MD,Rahul Banerjee, MD, FACP,Krina Patel, MD, MSc ,Tiffany Richards, PhD, ANP-BC, AOCNP ,Rafael Fonseca, MD,Sridevi Rajeeve, MD ,C. Ola Landgren, MD, PhD

Panelists discuss how to select appropriate bispecific antibody therapies for patients with relapsed/refractory multiple myeloma who have failed BCMA-targeted treatments, considering factors such as alternative targets, mechanisms of resistance, and emerging clinical data to provide effective subsequent treatment options.

9 Experts are featured in this series.

Sequencing Therapies for Relapsed Refractory Multiple Myeloma: Bispecifics or CAR T-cell Therapy

ByEhsan Malek, MD ,Peter Leif Bergsagel, MD,Rahul Banerjee, MD, FACP,Krina Patel, MD, MSc ,Tiffany Richards, PhD, ANP-BC, AOCNP ,Rafael Fonseca, MD,Sridevi Rajeeve, MD ,C. Ola Landgren, MD, PhD

Panelists discuss how to optimize the sequencing of bispecific antibodies and CAR T-cell therapies in relapsed/refractory multiple myeloma, considering factors such as patient characteristics, disease burden, and the unique advantages of each approach to maximize treatment efficacy and patient outcomes.

9 Experts are featured in this series.

Patient Case: A 67-Year-Old, BCMA-Naïve, Woman with Relapsed Refractory Multiple Myeloma

ByEhsan Malek, MD ,Peter Leif Bergsagel, MD,Rahul Banerjee, MD, FACP,Krina Patel, MD, MSc ,Tiffany Richards, PhD, ANP-BC, AOCNP ,Rafael Fonseca, MD,Sridevi Rajeeve, MD ,C. Ola Landgren, MD, PhD

Panelists discuss how to tailor treatment strategies for a 67-year-old, BCMA-naïve woman with relapsed/refractory multiple myeloma, weighing the potential benefits of BCMA-targeted therapies against other available options in the context of her specific clinical presentation.

9 Experts are featured in this series.

Patient Case: A 68-Year-Old Woman with Triple Class Exposed Relapsed Refractory Multiple Myeloma

ByEhsan Malek, MD ,Peter Leif Bergsagel, MD,Rahul Banerjee, MD, FACP,Krina Patel, MD, MSc ,Tiffany Richards, PhD, ANP-BC, AOCNP ,Rafael Fonseca, MD,Sridevi Rajeeve, MD ,C. Ola Landgren, MD, PhD

Panelists discuss how to approach treatment decisions for a 68-year-old woman with triple-class exposed relapsed/refractory multiple myeloma, considering factors such as prior therapies, disease characteristics, and emerging treatment options to optimize her care.

9 Experts are featured in this series.

CARTITUDE-4: Cilta-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma

ByEhsan Malek, MD ,Peter Leif Bergsagel, MD,Rahul Banerjee, MD, FACP,Krina Patel, MD, MSc ,Tiffany Richards, PhD, ANP-BC, AOCNP ,Rafael Fonseca, MD,Sridevi Rajeeve, MD ,C. Ola Landgren, MD, PhD

Panelists discuss how the CARTITUDE-4 trial results show cilta-cel's superior efficacy over standard of care therapies in treating relapsed/refractory multiple myeloma, potentially reshaping treatment paradigms for this patient population.

9 Experts are featured in this series.

KarMMa-3: Ide-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma

ByEhsan Malek, MD ,Peter Leif Bergsagel, MD,Rahul Banerjee, MD, FACP,Krina Patel, MD, MSc ,Tiffany Richards, PhD, ANP-BC, AOCNP ,Rafael Fonseca, MD,Sridevi Rajeeve, MD ,C. Ola Landgren, MD, PhD

Panelists discuss how the KarMMa-3 trial results demonstrate superior efficacy of ide-cel compared to standard of care therapies in patients with relapsed/refractory multiple myeloma, potentially establishing a new benchmark for treatment in this setting.

9 Experts are featured in this series.

Ide-Cel: Real-World Outcomes for Relapsed Refractory Multiple Myeloma

ByEhsan Malek, MD ,Peter Leif Bergsagel, MD,Rahul Banerjee, MD, FACP,Krina Patel, MD, MSc ,Tiffany Richards, PhD, ANP-BC, AOCNP ,Rafael Fonseca, MD,Sridevi Rajeeve, MD ,C. Ola Landgren, MD, PhD

Panelists discuss how ide-cel, a CAR T-cell therapy, demonstrates promising real-world outcomes in patients with relapsed/refractory multiple myeloma, potentially offering a valuable treatment option for this challenging patient population.

9 Experts are featured in this series.

Treatment Strategies in Relapsed Refractory Multiple Myeloma

ByEhsan Malek, MD ,Peter Leif Bergsagel, MD,Rahul Banerjee, MD, FACP,Krina Patel, MD, MSc ,Tiffany Richards, PhD, ANP-BC, AOCNP ,Rafael Fonseca, MD,Sridevi Rajeeve, MD ,C. Ola Landgren, MD, PhD

Panelists discuss how novel therapeutic approaches and combination regimens are reshaping the landscape of treatment for patients with relapsed/refractory multiple myeloma, offering new hope for improved outcomes and quality of life.

Latest Updated Articles